MAGRIT 109493: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer

Summary:
Studies have shown that non-small cell lung cancer subjects who express the MAGE-A3 protein are prone to shorter survival and higher recurrence rate (cancer that comes back).  This study is being done to test an investigational product called MAGE-A3 ASCI to see if it may prevent recurrence of cancer after surgery has been done.  MAGE-A3 ASCI teaches your own body (immune system) to fight the cancer in the same way that it fights an infection by germs or viruses.  After treatment with this product, the immune system will target any cells that have the MAGE-A3 protein and attempt to remove it, thus killing any cancer cells that reappear with this protein.

Eligibility:

1. The non-small cell lung cancer subject’s tumor shows expression of MAGE-A3 gene.
2. The subject is free of metastasis.
3. Subject must be at least 18 years old.
4. Adequate bone-marrow reserve, adequate renal function and adequate hepatic function.

Please call for more information